USPTO serial 79020265
Serial No. 79020265
Reviewed by CopyMark Law Group
Reg. 3223297Status 706Renewal
- Filing date
- Status date
- Registration date
- Mar 27, 2007
- Examiner
- LAPTER, ALAIN J
- Law office
- GENERIC WEB UPDATE
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with Serial No. 79020265?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
NORTH CHINA PHARMACEUTICAL GROUP; CORPORATION
Shi Jiazhuang City, CN
Other trademarks owned by NORTH CHINA PHARMACEUTICAL GROUP; CORPORATION
NORTH CHINA PHARMACEUTICAL GROUP; CORPORATION
CN
Other trademarks owned by NORTH CHINA PHARMACEUTICAL GROUP; CORPORATION
NORTH CHINA PHARMACEUTICAL CO., LTD
CN
Other trademarks owned by NORTH CHINA PHARMACEUTICAL CO., LTD
NORTH CHINA PHARMACEUTICAL GROUP; CORPORATION
CN
Other trademarks owned by NORTH CHINA PHARMACEUTICAL GROUP; CORPORATION
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Western medicine and patent medicine, namely, antibiotics, synthetic antibacterial, antiviral, tuberculosis drugs, cardio-cerebrovascular system drugs, cancer drugs, gastrointestinal tract drugs, vitamins, urinary system drugs, coenzyme and biochemical drugs, immunity drugs, antipsychotic drugs, acetaminophen, for the treatment of acute bronchitis, infective endocarditis, cutaneous abscesses, necrotizing subcutaneous infections, lymphadenitis, gonorrhea, mycoplasmal pneumonia, pneumonia, lung abscess, pulmonary tuberculosis, pyogenic ostcomyclitis, septicemia, pyelonephritis, nephritis, urinary infection, phlegmon, peritonsillar abscess, purulent arthritis, pyogenic ostcomyclitis, purulent meningitis, scarlet fever, syphilis, typhoid, influenza, infantile diarrhea, gastric ulcer, gastritis, cardiac arrhythmias, angina pectoris, arteriosclerosis, hyperlipemia, hypertension, cerebral thrombosis, peripheral neuropathies, megaloblastic anemia, iron deficiency anemia, immunosuppressive agent, diabetes mellitus, hepatitis, carcinoma of stomach; biochemical medicine, namely, recombinant human granulocyte-macrophage colony stimulating factor for injection for the prevention and treatment of leukocytopenia caused by chemotherapy or radiotherapy in cancer patients, recombinant human granulocyte colony stimulating factor injection for prevention and treatment of leukopenia caused by chemotherapy or radiotherapy, and neutrupenia following transplantation of bone marrow, recombinant human erythropoetin injection used for anemia cause by renal insufficiency, including patients with chronic renal failure treated with or without hemodialysis, recombinant hepatitis B surface antigen vaccines to get rid of the contamination of viruses contained in human blood; tonics in the nature of medicine, for the treatment of acute bronchitis, infective endocarditis, cutaneous abscesses, necrotizing subcutaneous infections, lymphadenitis, gonorrhea, mycoplasmal pneumonia, pneumonia, lung abscess, pulmonary tuberculosis, pyogenic ostcomyclitis, septicemia, pyelonephritis, nephritis, urinary infection, phlegmon, peritonsillar abscess, purulent arthritis, pyogenic ostcomyclitis, purulent meningitis, scarlet fever, syphilis, typhoid, influenza, infantile diarrhea, gastric ulcer, gastritis, cardiac arrhythmias, angina pectoris, arteriosclerosis, hyperlipemia, hypertension, cerebral thrombosis, peripheral neuropathies, megaloblastic anemia, iron deficiency anemia, immunosuppressive agent, diabetes mellitus, hepatitis, carcinoma of stomach; dietetic substances adapted for medical use, for the treatment of acute bronchitis, infective endocarditis, cutaneous abscesses, necrotizing subcutaneous infections, lymphadenitis, gonorrhea, mycoplasmal pneumonia, pneumonia, lung abscess, pulmonary tuberculosis, pyogenic ostcomyclitis, septicemia, pyelonephritis, nephritis, urinary infection, phlegmon, peritonsillar abscess, purulent arthritis, pyogenic ostcomyclitis, purulent meningitis, scarlet fever, syphilis, typhoid, influenza, infantile diarrhea, gastric ulcer, gastritis, cardiac arrhythmias, angina pectoris, arteriosclerosis, hyperlipemia, hypertension, cerebral thrombosis, peripheral neuropathies, megaloblastic anemia, iron deficiency anemia, immunosuppressive agent, diabetes mellitus, hepatitis, carcinoma of stomach; dietetic foods adapted for medical purposes; diagnostic preparations for medical purposes preparations for acute bronchitis, infective endocarditis, cutaneous abscesses, necrotizing subcutaneous infections, lymphadenitis, gonorrhea, mycoplasmal pneumonia, pneumonia, lung abscess, pulmonary tuberculosis, pyogenic ostcomyclitis, septicemia, pyelonephritis, nephritis, urinary infection, phlegmon, peritonsillar abscess, purulent arthritis, pyogenic ostcomyclitis, purulent meningitis, scarlet fever, syphilis, typhoid, influenza, infantile diarrhea, gastric ulcer, gastritis, cardiac arrhythmias, angina pectoris, arteriosclerosis, hyperlipemia, hypertension, cerebral thrombosis, peripheral neuropathies, megaloblastic anemia, iron deficiency anemia, immunosuppressive agent, diabetes mellitus, hepatitis, carcinoma of stomach; fodder additives for medical purposes; nutritional additives for medical purposes; baby food; medical kits, comprising of antibiotics, synthetic antibacterial, antiviral, tuberculosis drugs, cardio-cerebrovascular system drugs, cancer drugs, gastrointestinal tract drugs, vitamins, urinary system drugs, coenzyme and biochemical drugs, immunity drugs, antipsychotic drugs, acetaminophen; all kinds of pills all included in this class, in the nature of antibiotics, synthetic antibacterial, antiviral, tuberculosis drugs, cardio-cerebrovascular system drugs, cancer drugs, gastrointestinal tract drugs, vitamins, urinary system drugs, coenzyme and biochemical drugs, immunity drugs, antipsychotic drugs, acetaminophen; insecticides; germicides; herbicides; agrochemical herbicides; gelatin for medical purposes; pectin containing preparations for pharmaceutical purposes, namely, antibiotics, synthetic antibacterial, antiviral, tuberculosis drugs, cardio-cerebrovascular system drugs, cancer drugs, gastrointestinal tract drugs, vitamins, urinary system drugs, coenzyme and biochemical drugs, immunity drugs, antipsychotic drugs, acetaminophen, for the treatment of acute bronchitis, infective endocarditis, cutaneous abscesses, necrotizing subcutaneous infections, lymphadenitis, gonorrhea, mycoplasmal pneumonia, pneumonia, lung abscess, pulmonary tuberculosis, pyogenic ostcomyclitis, septicemia, pyelonephritis, nephritis, urinary infection, phlegmon, peritonsillar abscess, purulent arthritis, pyogenic ostcomyclitis, purulent meningitis, scarlet fever, syphilis, typhoid, influenza, infantile diarrhea, gastric ulcer, gastritis, cardiac arrhythmias, angina pectoris, arteriosclerosis, hyperlipemia, hypertension, cerebral thrombosis, peripheral neuropathies, megaloblastic anemia, iron deficiency anemia, immunosuppressive agent, diabetes mellitus, hepatitis, carcinoma of stomach; veterinary medicine, namely, blood serum for veterinary purpose, vaccines for veterinary purpose, diagnosticum for veterinary purpose, chemical material medicine for veterinary purpose, chemical preparations for veterinary purpose, antibiotics for veterinary purpose, biomedicine for veterinary purpose, radioactivity drug for veterinary purpose; medicine, namely, antibiotics, synthetic antibacterial, antiviral, tuberculosis drugs, cardio-cerebrovascular system drugs, cancer drugs, gastrointestinal tract drugs, vitamins, urinary system drugs, coenzyme and biochemical drugs, immunity drugs, antipsychotic drugs, acetaminophen, for the treatment of acute bronchitis, infective endocarditis, cutaneous abscesses, necrotizing subcutaneous infections, lymphadenitis, gonorrhea, mycoplasmal pneumonia, pneumonia, lung abscess, pulmonary tuberculosis, pyogenic ostcomyclitis, septicemia, pyelonephritis, nephritis, urinary infection, phlegmon, peritonsillar abscess, purulent arthritis, pyogenic ostcomyclitis, purulent meningitis, scarlet fever, syphilis, typhoid, influenza, infantile diarrhea, gastric ulcer, gastritis, cardiac arrhythmias, angina pectoris, arteriosclerosis, hyperlipemia, hypertension, cerebral thrombosis, peripheral neuropathies, megaloblastic anemia, iron deficiency anemia, immunosuppressive agent, diabetes mellitus, hepatitis, carcinoma of stomach; Chinese medicine material, namely, antibiotics, synthetic antibacterial, antiviral, tuberculosis drugs, cardio-cerebrovascular system drugs, cancer drugs, gastrointestinal tract drugs, vitamins, urinary system drugs, coenzyme and biochemical drugs, immunity drugs, antipsychotic drugs, acetaminophen; medical plasters; sanitary sterilizing preparations; isopropyl alcohol for medical use; glucose tablets used as a dietary supplement; starch for pharmaceutical purposes, namely, antibiotics, synthetic antibacterial, antiviral, tuberculosis drugs, cardio-cerebrovascular system drugs, cancer drugs, gastrointestinal tract drugs, vitamins, urinary system drugs, coenzyme and biochemical drugs, immunity drugs, antipsychotic drugs, acetaminophen, for the treatment of acute bronchitis, infective endocarditis, cutaneous abscesses, necrotizing subcutaneous infections, lymphadenitis, gonorrhea, mycoplasmal pneumonia, pneumonia, lung abscess, pulmonary tuberculosis, pyogenic ostcomyclitis, septicemia, pyelonephritis, nephritis, urinary infection, phlegmon, peritonsillar abscess, purulent arthritis, pyogenic ostcomyclitis, purulent meningitis, scarlet fever, syphilis, typhoid, influenza, infantile diarrhea, gastric ulcer, gastritis, cardiac arrhythmias, angina pectoris, arteriosclerosis, hyperlipemia, hypertension, cerebral thrombosis, peripheral neuropathies, megaloblastic anemia, iron deficiency anemia, immunosuppressive agent, diabetes mellitus, hepatitis, carcinoma of stomach; primary medicine of western medicine, namely, antibiotics, synthetic antibacterial, antiviral, tuberculosis drugs, cardio-cerebrovascular system drugs, cancer drugs, gastrointestinal tract drugs, vitamins, urinary system drugs, coenzyme and biochemical drugs, immunity drugs, antipsychotic drugs, acetaminophen, for the treatment of acute bronchitis, infective endocarditis, cutaneous abscesses, necrotizing subcutaneous infections, lymphadenitis, gonorrhea, mycoplasmal pneumonia, pneumonia, lung abscess, pulmonary tuberculosis, pyogenic ostcomyclitis, septicemia, pyelonephritis, nephritis, urinary infection, phlegmon, peritonsillar abscess, purulent arthritis, pyogenic ostcomyclitis, purulent meningitis, scarlet fever, syphilis, typhoid, influenza, infantile diarrhea, gastric ulcer, gastritis, cardiac arrhythmias, angina pectoris, arteriosclerosis, hyperlipemia, hypertension, cerebral thrombosis, peripheral neuropathies, megaloblastic anemia, iron deficiency anemia, immunosuppressive agent, diabetes mellitus, hepatitis, carcinoma of stomach | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NORTH CHINA PHARMACEUTICAL GROUP; CORPORATION
- Other trademarks owned by NORTH CHINA PHARMACEUTICAL GROUP; CORPORATION
- Other trademarks owned by NORTH CHINA PHARMACEUTICAL CO., LTD
- Other trademarks owned by NORTH CHINA PHARMACEUTICAL GROUP; CORPORATION
- Other trademarks in Class 005
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 27, 2026 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| May 15, 2025 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Jun 11, 2021 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Mar 18, 2017 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Mar 18, 2017 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Mar 17, 2017 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Mar 17, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 27, 2016 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Jul 16, 2015 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Apr 3, 2013 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Apr 3, 2013 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Apr 3, 2013 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Mar 19, 2013 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Mar 19, 2013 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 19, 2013 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 6, 2008 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 25, 2007 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 25, 2007 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Sep 19, 2007 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 27, 2007 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 9, 2007 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 20, 2006 | NPUB | NOTICE OF PUBLICATION | — |
| Nov 20, 2006 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 9, 2006 | ALIE | ASSIGNED TO LIE | — |
| Nov 7, 2006 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 25, 2006 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Sep 15, 2006 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 15, 2006 | PAPER RECEIVED | — | |
| Apr 7, 2006 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 15, 2006 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 15, 2006 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 10, 2006 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 9, 2006 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 6, 2006 | NWAP | NEW APPLICATION ENTERED | — |
| Mar 2, 2006 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |